FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:980-982 April 2, 1998 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Hansen, J. A. PubMed Citation

Transplantation of marrow from an unrelated donor offers the possibility of a cure for the 70 percent of patients with chronic myeloid leukemia (CML) who can tolerate the procedure and for whom a related donor is unavailable.¹ The probability of finding an unrelated donor with HLA-A, B, and DR antigens that serologically match those of the recipient is about 80 percent within an 80-day period, thanks to the nearly 5 million volunteers enrolled in bone marrow–donor registries worldwide (Goldmann SS: personal communication). Despite these optimistic prospects, the actual results of treating CML with bone marrow from unrelated donors have been . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A., Hasford, J., Kolb, H.-J., Lahaye, T., Maywald, O., Reiter, A., Hossfeld, D. K., Huber, C., Loffler, H., Pralle, H., Queisser, W., Tobler, A., Nerl, C., Solenthaler, M., Goebeler, M. E., Griesshammer, M., Fischer, T., Kremers, S., Eimermacher, H., Pfreundschuh, M., Hirschmann, W.-D., Lechner, K., Wassmann, B., Falge, C., Kirchner, H. H., Gratwohl, A., for the Schweizerische Arbeitsgemeinschaft fur Kli, (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109: 4686-4692 [Abstract] [Full Text]  
• Chang, G., Orav, E. J., McNamara, T. K., Tong, M.-Y., Antin, J. H. (2005). Psychosocial Function After Hematopoietic Stem Cell Transplantation. Psychosomatics 46: 34-40 [Abstract] [Full Text]  
• Hehlmann, R., Hochhaus, A., Kolb, H.-J., Hasford, J., Gratwohl, A., Heimpel, H., Siegert, W., Finke, J., Ehninger, G., Holler, E., Berger, U., Pfirrmann, M., Muth, A., Zander, A., Fauser, A. A., Heyll, A., Nerl, C., Hossfeld, D. K., Loffler, H., Pralle, H., Tobler, W. Q.{b.}e. a. A. (1999). Interferon-alpha Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure. Blood 94: 3668-3677 [Abstract] [Full Text]